Voice of the Patient Meetings

To bring the patient perspective to the forefront of the drug development process, the GBS|CIDP Foundation International has hosted 2 Externally-Led Patient Focused Drug Development (EL PFDD) Meetings.

Patient-Focused Drug Development (PFDD) is a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.

One of FDA’s missions is to protect and promote public health by evaluating the safety and effectiveness of new drugs, biologics, and devices. FDA does not develop drugs nor conduct clinical trials. FDA does, however, play a constructive role in guiding, helping, or evaluating at some stages of the pre-clinical, translational, and clinical development work.

Learn more about EL PFDD Meetings

EL PFDD Meeting on Anti-MAG, GBS, and MMN

Thursday, May 16, 2024

The GBS|CIDP Foundation International hosted an EL PFDD Meeting on May 16th, 2024 to elevate the patient voice of those with Anti-MAG, GBS, and MMN. With an audience consisting of regulators and researchers who are involved in the drug development process, this meeting highlighted the needs and preferences of the Anti-MAG, GBS, and MMN patient communities.

Access the Recording Here

View the Agenda

Meet the Panelists

Anti-MAG Panelists

GBS Panelists

MMN Panelists

Thank You to Our Sponsors!

EL PFDD Meeting on CIDP

Friday, March 25, 2022

The GBS|CIDP Foundation International hosted our first EL PFDD Meeting on CIDP on Friday, March 25th, 2022. With the hope of better understanding CIDP patients’ preferences about treatments and their side effects we elevated the patient voice in this virtual meeting.

Access the 2022 Voice of the Patient Report Here

View the Agenda

Meet the Panelists

Diagnosis and Current Treatment Panelists

Everyday Burden Panelists

Patient Centered Trial Design Panelists

Potential Future of CIDP Treatment Panelists

Thank You to Our Sponsors!